Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy

Daniel C Malone, A. T. Luskin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Inhaled corticosteroids for asthma treatment have become mainstay of therapy for patients with persistent asthma. Numerous inhaled corticosteroids are available but to date no prospective cost-effectiveness studies have been reported using exclusively US patients and costs. The purpose of this study was to examine the cost-effectiveness of HFA-beclomethasone (QVAR™) compared to CFC-beclomethasone (Vanceril™) using data from a year-long prospective randomized, open label, parallel multicenter trial. Eligibility criteria required patients to have been on a stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-effectiveness analysis conducted from the viewpoint of managed care. Patients receiving HFA-BDP reported a greater increase (median = 22.1) in the number of SFDs than those receiving CFC-BDP (median = 14.3) (P = 0.03). Total costs of care were less for patients taking HFA-BDP (median = $668) compared to CFC-BDP (median = $977). The median incremental cost-effectiveness ratio was -$5.77 (95% CI:-$68.08 to -$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP.

Original languageEnglish (US)
Pages (from-to)1269-1276
Number of pages8
JournalRespiratory Medicine
Volume97
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

HFA 134a
Beclomethasone
Asthma
Economics
Cost-Benefit Analysis
Adrenal Cortex Hormones
Therapeutics
Costs and Cost Analysis
Managed Care Programs
Multicenter Studies

Keywords

  • Asthma
  • Beclomethasone
  • CFC-free
  • Cost-effectiveness
  • Economics
  • Hydrofluoroalkane

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. / Malone, Daniel C; Luskin, A. T.

In: Respiratory Medicine, Vol. 97, No. 12, 12.2003, p. 1269-1276.

Research output: Contribution to journalArticle

@article{585b69d422ed41b29f2e61785d98d199,
title = "Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy",
abstract = "Inhaled corticosteroids for asthma treatment have become mainstay of therapy for patients with persistent asthma. Numerous inhaled corticosteroids are available but to date no prospective cost-effectiveness studies have been reported using exclusively US patients and costs. The purpose of this study was to examine the cost-effectiveness of HFA-beclomethasone (QVAR™) compared to CFC-beclomethasone (Vanceril™) using data from a year-long prospective randomized, open label, parallel multicenter trial. Eligibility criteria required patients to have been on a stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-effectiveness analysis conducted from the viewpoint of managed care. Patients receiving HFA-BDP reported a greater increase (median = 22.1) in the number of SFDs than those receiving CFC-BDP (median = 14.3) (P = 0.03). Total costs of care were less for patients taking HFA-BDP (median = $668) compared to CFC-BDP (median = $977). The median incremental cost-effectiveness ratio was -$5.77 (95{\%} CI:-$68.08 to -$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP.",
keywords = "Asthma, Beclomethasone, CFC-free, Cost-effectiveness, Economics, Hydrofluoroalkane",
author = "Malone, {Daniel C} and Luskin, {A. T.}",
year = "2003",
month = "12",
doi = "10.1016/j.rmed.2003.07.006",
language = "English (US)",
volume = "97",
pages = "1269--1276",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy

AU - Malone, Daniel C

AU - Luskin, A. T.

PY - 2003/12

Y1 - 2003/12

N2 - Inhaled corticosteroids for asthma treatment have become mainstay of therapy for patients with persistent asthma. Numerous inhaled corticosteroids are available but to date no prospective cost-effectiveness studies have been reported using exclusively US patients and costs. The purpose of this study was to examine the cost-effectiveness of HFA-beclomethasone (QVAR™) compared to CFC-beclomethasone (Vanceril™) using data from a year-long prospective randomized, open label, parallel multicenter trial. Eligibility criteria required patients to have been on a stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-effectiveness analysis conducted from the viewpoint of managed care. Patients receiving HFA-BDP reported a greater increase (median = 22.1) in the number of SFDs than those receiving CFC-BDP (median = 14.3) (P = 0.03). Total costs of care were less for patients taking HFA-BDP (median = $668) compared to CFC-BDP (median = $977). The median incremental cost-effectiveness ratio was -$5.77 (95% CI:-$68.08 to -$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP.

AB - Inhaled corticosteroids for asthma treatment have become mainstay of therapy for patients with persistent asthma. Numerous inhaled corticosteroids are available but to date no prospective cost-effectiveness studies have been reported using exclusively US patients and costs. The purpose of this study was to examine the cost-effectiveness of HFA-beclomethasone (QVAR™) compared to CFC-beclomethasone (Vanceril™) using data from a year-long prospective randomized, open label, parallel multicenter trial. Eligibility criteria required patients to have been on a stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-effectiveness analysis conducted from the viewpoint of managed care. Patients receiving HFA-BDP reported a greater increase (median = 22.1) in the number of SFDs than those receiving CFC-BDP (median = 14.3) (P = 0.03). Total costs of care were less for patients taking HFA-BDP (median = $668) compared to CFC-BDP (median = $977). The median incremental cost-effectiveness ratio was -$5.77 (95% CI:-$68.08 to -$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP.

KW - Asthma

KW - Beclomethasone

KW - CFC-free

KW - Cost-effectiveness

KW - Economics

KW - Hydrofluoroalkane

UR - http://www.scopus.com/inward/record.url?scp=0348111302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348111302&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2003.07.006

DO - 10.1016/j.rmed.2003.07.006

M3 - Article

C2 - 14682406

AN - SCOPUS:0348111302

VL - 97

SP - 1269

EP - 1276

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 12

ER -